Experte findet Corona-Lage im Herbst schwierig vorherzusagen vol.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vol.at Daily Mail and Mail on Sunday newspapers.
Reuters Reuters
21 July, 2021, 2:10 pm
Vials labelled Moderna, Johnson & Johnson, Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are seen in this illustration picture taken May 2, 2021. REUTERS/Dado Ruvic
CHICAGO, July 20 (Reuters) – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks – known as correlates of protection – to evaluate flu vaccines without requiring large, lengthy clinical trials.
Jul 21, 2021
CHICAGO – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks known as correlates of protection to evaluate flu vaccines without requiring large, lengthy clinical trials.
“You could use it to predict efficacy from a vaccine, which will be more important as we are less able to conduct placebo-controlled trials,” said Stanley Plotkin, inventor of the Rubella vaccine and an expert on correlates of protection.
Correlates of Protection: The Holy Grail of COVID-19 Immunity theatlantic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theatlantic.com Daily Mail and Mail on Sunday newspapers.